REGENXBIO Stock Plunges 25% on FDA Clinical Hold for Gene Therapy

Key Facts

1REGENXBIO stock plunged 25% after the FDA placed a clinical hold on its RGX-121 gene therapy for MPS II.

2The clinical hold followed asymptomatic spine MRI findings in five trial participants.

In a move reflecting the high sensitivity of the biotech sector to regulatory hurdles, REGENXBIO faced intense selling pressure that drove its stock down by 25%. This sharp decline followed the U.S. Food and Drug Administration (FDA) placing a clinical hold on trials for RGX-121, a gene therapy candidate for Hunter syndrome (MPS II). According to reports, the regulatory body took this action as a precautionary measure to evaluate patient safety following abnormal screening results.

The clinical hold was triggered by asymptomatic spine MRI findings observed in five trial participants. This development represents a significant setback for the company's pipeline, as RGX-121 is a primary candidate in its therapeutic portfolio. Per market dynamics, the investor reaction underscores serious concerns regarding the development timeline of this gene therapy and its potential impact on the company's overall valuation.

Traders are currently monitoring the company's ability to address FDA concerns to resume trials, noting that updated price levels were unavailable at the close of August 25, 2026. Looking ahead at the economic calendar, investors are awaiting the FOMC Minutes on August 19, 2026, which may influence broader risk appetite across the growth and biotech sectors.

Sources:

zacks.com